Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Melphalan 5Filgrastim 4birtamimab 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pomalidomide 2Calcium Dobesilate 2Bortezomib 2venetoclax 1pegfilgrastim 1nelarabine 1melflufen 1daratumumab 1Tetradecanoylphorbol Acetate 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Moxifloxacin 1Morphine 1Methadone 1Fluorescent Antibody Technique 1Fentanyl 1Diuretics 1Ciprofloxacin 1Blood Component Removal 1Amoxicillin-Potassium Clavulanate Combination 1Amifostine 14'-deoxy-4'-iododoxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immunoglobulin Light-chain Amyloidosis × 4'-deoxy-4'-iododoxorubicin × Clear all
NCT00030381 2013-01-16

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡